UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
Public ClinicalTrials.gov record NCT00574080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Study identification
- NCT ID
- NCT00574080
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Interim/Maintenance Dexamethasone Drug
- Induction/Consolidation Dexamethasone Drug
- Induction/Consolidation Cisplatin Drug
- Induction/Consolidation Adriamycin Drug
- InductionConsolidation Cyclophosphamide Drug
- Induction/Consolidation Etoposide Drug
- Induction Pegfilgrastim Drug
- Transplant 1 Dexamethasone Drug
- Transplant 1 Cisplatin Drug
- Transplant 1 Adriamycin Drug
- Transplant 1 Cyclophosphamide Drug
- Transplant 1 Etoposide Drug
- Transplant 1 Melphalan Drug
- Transplant 1 and 2 Pegfilgrastim Drug
- Autologous Peripheral Blood Stem Cell Transplant (ASCT) Procedure
- Transplant 2 Carmustine Drug
- Transplant 2 Etoposide Drug
- Transplant 2 Cytarabine Drug
- Transplant 2 Melphalan Drug
- Transplant 2 Dexamethasone Drug
- Transplant 1 and 2 Bortezomib Drug
- Transplant 1 and 2 Thalidomide Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- Nov 19, 2017
2006 – 2011
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00574080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2017 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00574080 live on ClinicalTrials.gov.